Here’s a plain-English summary of the article titled “Liver Imaging Reporting and Data System (LI-RADS): A Comprehensive Review,” from Cureus, dated 07/31/2026, for patients and families:
Understanding LI-RADS: A Guide for Patients
Source: Liver Imaging Reporting and Data System (LI-RADS): A Comprehensive Review (Cureus, 2026)
What is LI-RADS?
LI-RADS (pronounced “lie-rads”) is a standardized scoring system that radiologists use when reading liver CT scans, MRIs, and certain ultrasounds.
Its purpose is simple:
Estimate how likely it is that a spot (lesion) in the liver is liver cancer (hepatocellular carcinoma, or HCC).
Think of it like the BI-RADS system used for mammograms.
It helps every doctor speak the same language.
Who is LI-RADS used for?
LI-RADS is not used for everyone.
It is mainly for people at high risk of liver cancer, including those with:
- Cirrhosis
- Chronic hepatitis B
- A previous liver cancer
If someone has a healthy liver without these conditions, LI-RADS usually does not apply.
The LI-RADS Score
LR-1: Definitely Not Cancer
The spot is harmless.
Examples:
- Cyst
- Hemangioma (a common benign blood vessel growth)
Usually no special treatment is needed.
LR-2: Probably Not Cancer
Very unlikely to be cancer.
Doctors usually just keep watching it with routine imaging.
LR-3: Uncertain
This is the “gray zone.”
The spot has some features that raise concern, but not enough to diagnose cancer.
Many LR-3 lesions never become cancer.
Doctors often recommend:
- Repeat MRI or CT in 3–6 months
- Sometimes additional testing
LR-4: Probably Cancer
The imaging strongly suggests liver cancer.
Doctors usually recommend:
- More imaging
- Sometimes biopsy
- Evaluation by a liver specialist
LR-5: Definitely Liver Cancer
This is the highest category.
An LR-5 lesion has imaging features that are so typical of liver cancer that many patients do not even need a biopsy.
Treatment planning usually begins immediately.
LR-M
“M” stands for Malignant, but not necessarily typical liver cancer.
It may represent:
- Cholangiocarcinoma (bile duct cancer)
- Metastatic cancer
- Other uncommon tumors
These usually require biopsy.
LR-TIV
This means the cancer has grown into a blood vessel (tumor in vein).
This represents more advanced disease and changes treatment options.
How do doctors decide?
Radiologists look for several key imaging features, including:
- Does the lesion brighten quickly after contrast?
- Does it lose contrast later (“washout”)?
- Is there a capsule around it?
- Has it grown?
- How large is it?
The combination determines the LI-RADS category.
Does an LR-5 score always mean cancer?
Almost always.
Studies show LR-5 has very high specificity, meaning false positives are uncommon.
That’s why many patients can proceed directly to treatment without biopsy.
Does everyone with cirrhosis get LI-RADS?
No.
LI-RADS is only used when a suspicious lesion is seen on imaging.
People with cirrhosis often undergo routine ultrasound every six months to look for these lesions.
Why is LI-RADS important?
Before LI-RADS, different hospitals used different language.
Now:
- Radiologists classify findings the same way
- Hepatologists understand exactly what the scan means
- Surgeons and oncologists can plan treatment more consistently
- Patients receive more standardized care worldwide
What happens after each score?
| Score | What it usually means | Typical next step |
|---|---|---|
| LR-1 | Definitely benign | Routine follow-up |
| LR-2 | Probably benign | Routine surveillance |
| LR-3 | Uncertain | Repeat imaging in a few months |
| LR-4 | Probably liver cancer | Additional evaluation, sometimes biopsy |
| LR-5 | Liver cancer | Begin treatment planning |
| LR-M | Other type of cancer possible | Biopsy usually recommended |
| LR-TIV | Cancer has entered a vein | Advanced cancer treatment planning |
Bottom line
LI-RADS is a standardized “report card” for liver imaging. It helps doctors estimate the chance that a liver spot is cancer and guides the next steps. The higher the score, the greater the concern. An LR-5 result is considered highly reliable evidence of liver cancer in people who are already at high risk, while lower scores often lead to repeat imaging and monitoring rather than immediate treatment.
a